Two biopharmas, Alexion Pharmaceuticals and Karyopharm, are trialing possible treatments while Eli Lilly and Bristol Myers Squibb are offering to help the unemployed stay on their meds.
Meanwhile, President Donald Trump offered U.K. Prime MInister Boris Johnson, in the ICU with COVID-19, unproven treatments. And news emerged that Trump himself holds a small financial interest in Sanofi, which makes an off-patent brand of hydroxychloroquine.
India is reportedly retracting export bans on 13 active pharmaceutical ingredients and finished formulations, and hydroxychloroquine may be included.
As of Tuesday, the number of global confirmed cases had surpassed 1.36 million, according to Johns Hopkins University’s real-time dashboard, and nearly 76,000 people had died.
See all of FiercePharma’s COVID-19 coverage here
By Eric Sagonowsky, Kyle Blankenship, Angus Liu, Conor Hale
Source: Fierce Pharma
The deal will enhance Merck’s expertise in developing and manufacturing mRNA for its customers for use in vaccines, treatments and diagnostics applicable in Covid-19 and various other diseases.
It’s the first significant visual redesign for Pfizer in 70 years since the company began using the blue oval background. The tagline outlining Pfizer’s purpose, “Breakthroughs that change patients’ lives,” remains the same.
The massive growth of gene therapy research and development over the last few years has boosted demand for viral vectors, the engineered viruses used to deliver therapeutic genes into patients’ bodies. Tokyo-based Fujifilm Diosynth Biotechnologies is stepping up to meet that demand.
